Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

24.50 -2.17 (-8.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Crude Oil Moves Lower; Moderna Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Stock Of The Day: Moderna Stock Plunges, Breaking Key Support Levels Following Earnings Report
Shares of Moderna (MRNA) have broken an important support level. This means a new downtrend may be forming. 
Via Benzinga
Moderna (MRNA) Q2 2024 Earnings Call Transcript
MRNA earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks To Watch Today: MRNA, META, And AMAT
Meta Platforms surged on strong earnings and AI progress, while Moderna plummeted after slashing its sales outlook and Applied Materials saw its stock drop after being denied funding under the CHIPS... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna CEO Stephane Bancel On Q2 Results, Slashing Its Full-Year Sales Guidance
Moderna reported its latest quarterly earnings. 
Via Talk Markets
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Via ACCESSWIRE
Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years
Via Benzinga
David Rubenstein Joins Moderna's Board of Directors
Via ACCESSWIRE
Check Out What Whales Are Doing With MRNA
Via Benzinga
Moderna Stock Sinks On Lowered 2024 Outlook, Cites Low European Sales, Competitive RSV Vaccine Market
Moderna's stock drops after cutting 2024 sales forecast due to reduced COVID-19 vaccine demand. The company now expects net sales of $3-$3.5 billion. Q2 revenue hits $241 million, beating expectations,... 
Via Benzinga
Exposures COVID-19
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
Moderna delivered nearly double the sales analysts expected in the second quarter. 
Via Investor's Business Daily
Get Your Money Out of These 3 Biotech Stocks Before the End of July
These stocks are at a risk of providing negative returns to shareholders due to the several operational challenges faced by the companies. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Top Research Reports For Amazon.com, Prologis & Infosys
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Prologis, Inc. and Infosys Limited, as well as a micro-cap stock Blue Dolphin Energy Company. 
Via Talk Markets
Decoding Moderna's Options Activity: What's the Big Picture?
Via Benzinga
Is Moderna Stock a Buy?
The biotech is proving that it's not a pandemic stock. 
Via The Motley Fool
3 Flying Car Stocks That Could Be Multibaggers in the Making: July Edition
Discover three flying car stocks poised for significant growth. Explore key players and market insights in this comprehensive July edition. 
Via InvestorPlace
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept. 
Via Benzinga
Exposures COVID-19
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. 
Via InvestorPlace
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Exposures COVID-19
3 Biotech Stocks to Buy in Case of Another Pandemic
These are three of the best biotech stocks to keep an eye on as the industry helps governments prepare for the next pandemic. 
Via InvestorPlace
Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
Via Benzinga
2 Growth Stocks Down 25% to Buy Right Now
Discounted stock prices make these strong brands worth considering as investments. 
Via The Motley Fool
Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time
Avian influenza continues to spread among animals and has infected four dairy workers in the US. Concerns about human-to-human transmission are low. 
Via Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
Investors might want to consider the top pharma stocks in the current environment as they are beating most others. 
Via InvestorPlace
Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures
The funds are intended to launch a series of new biotech companies that will harness the power of generative artificial intelligence for drug discovery. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
Via ACCESSWIRE
Moderna To Collaborate With Mitsubishi On Respiratory Vaccine Promotion In Japan
Moderna and Mitsubishi signed a joint agreement regarding the co-promotion of Moderna's respiratory vaccine portfolio in Japan. 
Via Benzinga
Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
Via ACCESSWIRE
3 Healthcare Stocks to Sell in July Before They Crash & Burn
Many healthcare names are attractive. But drugstore chains and some drug makers have poor outlooks. Here are three healthcare stocks to sell. 
Via InvestorPlace
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.